BOSTON, MA--(Marketwire - September 03, 2008) - New drugs that receive fast track designation by the U.S. Food and Drug Administration (FDA) experience shorter clinical and approval times compared to drugs without the designation, according to a recently completed study of the first decade of the fast track program conducted by the Tufts Center for the Study of Drug Development.
